January 18th 2023
Highly effective medications for severe disease are expensive and administered invasively, while the development of treatments for milder disease has lagged, a new review on psoriasis clinical trials concludes.
September 20th 2022
Dupilumab Receives FDA Priority Review and Accepts sBLA for Children 6 Months to 5 YearsFebruary 10th 2022
If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate to severe atopic dermatitis for young children 6 months to 5 years old.
The Potential of Precision MedicineMarch 5th 2021
Taking the polar opposite of a one-size-fits-all approach, clinicians now factor in a patient’s genetic profile, medical history, microbiome composition, lifestyle, and diet, among other parameters, otherwise known as precision medicine.